Elranatamab
Pfizer
['mmsm']
reduction in soluble bcma levels were seen. orr of 64%, 28% &gt;cr, despite &gt;50% having prior anti-bcma therapy. median time to response of 36d. mdor 17.1m, 100% of responders were mrd-, many extending &gt;6m. pfs 11.8m. promising therapy
#ash22 #imfash22 #mmsm 
Hematology is in my ??. Posts are mine. Mayo Clinic Associate, Asst Prof, BMT RNCC, RN Navigator, emeritus. IMF NLB. MM KOL. Patient educator & advocate.